Abstract

The ability of probucol, a lipid-lowering drug with antioxidant properties, to prevent the Cu2+-induced oxidation of human plasma low density lipoproteins (LDL) was examined as a function of the concentration of probucol in LDL. In the absence of probucol, 3 microM Cu2+ induced half-maximal LDL lipid oxidation, as determined by the formation of thiobarbituric acid reactive substances (TBARS). Oxidation was associated with a loss of apolipoprotein B-100 and the appearance of higher molecular weight forms of the protein. In the presence of 0.6 mol% probucol (relative to phospholipid) and with 3 microM Cu2+, the time required to obtain half-maximal LDL lipid oxidation increased from 130 to 270 min and was explained by an increase in the lag time prior to LDL lipid oxidation. Once rapid oxidation of LDL had begun, the rate of TBARS formation was similar to that for LDL containing no probucol. At a probucol concentration of 4.2 mol%, the antioxidant prevented the oxidation of LDL-lipids. The delay in Cu2+-induced LDL oxidation with probucol corresponded to the time required for free radical-mediated processes to convert probucol to a spiroquinone and a diphenoquinone. These in vitro findings suggest that the potent antioxidant property of probucol is directly related to the amount of drug in the LDL particle and may have relevance to its antiatherosclerotic effects observed in vivo.

Highlights

  • The ability of probucol, a lipid-lowering drug with antioxidant properties, to prevent the Cu2'-induced oxidation of human plasma low density lipoproteins (LDL) was examined as a function of the concentration of probucol in LDL

  • We provide in vitro evidence that the concentration of probucol in LDL determines the extent of oxidative modification of the lipoprotein

  • The maximum amount of lipid peroxides generated in 14 h was 27 nmol MDA/mg LDL-protein with 10 pM Cu2+.The Cu2+concentration required for half-maximal oxidation was 3 pM

Read more

Summary

Introduction

The ability of probucol, a lipid-lowering drug with antioxidant properties, to prevent the Cu2'-induced oxidation of human plasma low density lipoproteins (LDL) was examined as a function of the concentration of probucol in LDL. We provide in vitro evidence that the concentration of probucol in LDL determines the extent of oxidative modification of the lipoprotein.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.